BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 17507624)

  • 1. Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer.
    Cunningham JM; Hebbring SJ; McDonnell SK; Cicek MS; Christensen GB; Wang L; Jacobsen SJ; Cerhan JR; Blute ML; Schaid DJ; Thibodeau SN
    Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):969-78. PubMed ID: 17507624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of the polymorphisms of genes involved in androgen metabolism and signaling pathways with familial prostate cancer risk in a Japanese population.
    Okugi H; Nakazato H; Matsui H; Ohtake N; Nakata S; Suzuki K
    Cancer Detect Prev; 2006; 30(3):262-8. PubMed ID: 16859836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial.
    Price DK; Chau CH; Till C; Goodman PJ; Leach RJ; Johnson-Pais TL; Hsing AW; Hoque A; Parnes HL; Schenk JM; Tangen CM; Thompson IM; Reichardt JK; Figg WD
    Cancer; 2016 Aug; 122(15):2332-40. PubMed ID: 27164191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women.
    MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk
    Breast Cancer Res Treat; 2010 Jan; 119(2):463-74. PubMed ID: 19424794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations between polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial.
    Tang L; Platek ME; Yao S; Till C; Goodman PJ; Tangen CM; Wu Y; Platz EA; Neuhouser ML; Stanczyk FZ; Reichardt JKV; Santella RM; Hsing A; Figg WD; Lippman SM; Thompson IM; Ambrosone CB
    Carcinogenesis; 2018 Feb; 39(2):125-133. PubMed ID: 29228205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variant in sex hormone-binding globulin gene and the risk of prostate cancer.
    Berndt SI; Chatterjee N; Huang WY; Chanock SJ; Welch R; Crawford ED; Hayes RB
    Cancer Epidemiol Biomarkers Prev; 2007 Jan; 16(1):165-8. PubMed ID: 17220347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women.
    Sangrajrang S; Sato Y; Sakamoto H; Ohnami S; Laird NM; Khuhaprema T; Brennan P; Boffetta P; Yoshida T
    Int J Cancer; 2009 Aug; 125(4):837-43. PubMed ID: 19415745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-alpha-reductase type 2 is important for prostate cancer development.
    Lindström S; Wiklund F; Adami HO; Bälter KA; Adolfsson J; Grönberg H
    Cancer Res; 2006 Nov; 66(22):11077-83. PubMed ID: 17108148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol-O-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population.
    Suzuki K; Nakazato H; Matsui H; Koike H; Okugi H; Kashiwagi B; Nishii M; Ohtake N; Nakata S; Ito K; Yamanaka H
    Cancer; 2003 Oct; 98(7):1411-6. PubMed ID: 14508827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying susceptibility genes for prostate cancer--a family-based association study of polymorphisms in CYP17, CYP19, CYP11A1, and LH-beta.
    Douglas JA; Zuhlke KA; Beebe-Dimmer J; Levin AM; Gruber SB; Wood DP; Cooney KA
    Cancer Epidemiol Biomarkers Prev; 2005 Aug; 14(8):2035-9. PubMed ID: 16103457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic polymorphism in sex hormone metabolism and prostate cancer risk.
    Ersekerci E; Sofikerim M; Taheri S; Demirtas A; Halis F
    Genet Mol Res; 2015 Jul; 14(3):7326-34. PubMed ID: 26214411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens.
    Cussenot O; Azzouzi AR; Nicolaiew N; Fromont G; Mangin P; Cormier L; Fournier G; Valeri A; Larre S; Thibault F; Giordanella JP; Pouchard M; Zheng Y; Hamdy FC; Cox A; Cancel-Tassin G
    J Clin Oncol; 2007 Aug; 25(24):3596-602. PubMed ID: 17704407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of androgen metabolism genes CYP1B1, PSA/KLK3, and CYP11alpha in prostate cancer risk and aggressiveness.
    Cicek MS; Liu X; Casey G; Witte JS
    Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2173-7. PubMed ID: 16172228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways.
    Latil AG; Azzouzi R; Cancel GS; Guillaume EC; Cochan-Priollet B; Berthon PL; Cussenot O
    Cancer; 2001 Sep; 92(5):1130-7. PubMed ID: 11571725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphisms of CYP1A1, GSTM1, GSTT1, and prostate cancer risk in Turkish population.
    Silig Y; Pinarbasi H; Günes S; Ayan S; Bagci H; Cetinkaya O
    Cancer Invest; 2006 Feb; 24(1):41-5. PubMed ID: 16466991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tobacco and estrogen metabolic polymorphisms and risk of non-small cell lung cancer in women.
    Cote ML; Yoo W; Wenzlaff AS; Prysak GM; Santer SK; Claeys GB; Van Dyke AL; Land SJ; Schwartz AG
    Carcinogenesis; 2009 Apr; 30(4):626-35. PubMed ID: 19174490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR.
    Cicek MS; Conti DV; Curran A; Neville PJ; Paris PL; Casey G; Witte JS
    Prostate; 2004 Apr; 59(1):69-76. PubMed ID: 14991867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic replication study of reported genetic associations in prostate cancer: Strong support for genetic variation in the androgen pathway.
    Lindström S; Zheng SL; Wiklund F; Jonsson BA; Adami HO; Bälter KA; Brookes AJ; Sun J; Chang BL; Liu W; Li G; Isaacs WB; Adolfsson J; Grönberg H; Xu J
    Prostate; 2006 Dec; 66(16):1729-43. PubMed ID: 16998812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of genetic polymorphisms of glutathione-S-transferase genes (GSTM1, GSTT1 and GSTP1) with familial prostate cancer risk in a Japanese population.
    Nakazato H; Suzuki K; Matsui H; Koike H; Okugi H; Ohtake N; Takei T; Nakata S; Hasumi M; Ito K; Kurokawa K; Yamanaka H
    Anticancer Res; 2003; 23(3C):2897-902. PubMed ID: 12926131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of genetic polymorphisms in ESR2, HSD17B1, ABCB1, and SHBG genes with colorectal cancer risk.
    Sainz J; Rudolph A; Hein R; Hoffmeister M; Buch S; von Schönfels W; Hampe J; Schafmayer C; Völzke H; Frank B; Brenner H; Försti A; Hemminki K; Chang-Claude J
    Endocr Relat Cancer; 2011 Apr; 18(2):265-76. PubMed ID: 21317201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.